Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low prevalence of the 'gang of seven' and absence of the O80:H2 serotypes among Shigatoxigenic and enteropathogenic Escherichia coli (STEC and EPEC) in intestinal contents of healthy cattle at two slaughterhouses in Belgium in 2014.
Thiry D, De Rauw K, Takaki S, Duprez JN, Iguchi A, Piérard D, Korsak N, Mainil JG. Thiry D, et al. Among authors: takaki s. J Appl Microbiol. 2018 Mar;124(3):867-873. doi: 10.1111/jam.13677. Epub 2018 Feb 2. J Appl Microbiol. 2018. PMID: 29280544 Free article.
Prediction of Hepatocellular Carcinoma After Hepatitis C Virus Sustained Virologic Response Using a Random Survival Forest Model.
Nakahara H, Ono A, Hayes CN, Shirane Y, Miura R, Fujii Y, Murakami S, Yamaoka K, Bao H, Uchikawa S, Fujino H, Murakami E, Kawaoka T, Miki D, Tsuge M, Oka S; Hiroshima Liver Study Group; TransSCOT Consortium. Nakahara H, et al. JCO Clin Cancer Inform. 2024 Dec;8:e2400108. doi: 10.1200/CCI.24.00108. Epub 2024 Dec 18. JCO Clin Cancer Inform. 2024. PMID: 39693579
Discrepancy between Subjective and Objective Measurements for the Evaluation of Medication Adherence-A Cross-Sectional Study in Patients with Cardiovascular Diseases.
Miyazaki M, Hirata H, Takaki S, Misaki M, Mori Y, Tokura K, Sato N, Nakashima A, Yanagida A, Okajima I, Urata H, Imakyure O. Miyazaki M, et al. Among authors: takaki s. Pharmacy (Basel). 2024 Oct 6;12(5):153. doi: 10.3390/pharmacy12050153. Pharmacy (Basel). 2024. PMID: 39452809 Free PMC article.
Effect of adequacy of empirical antibiotic therapy for hospital-acquired bloodstream infections on intensive care unit patient prognosis: a causal inference approach using data from the Eurobact2 study.
Loiodice A, Bailly S, Ruckly S, Buetti N, Barbier F, Staiquly Q, Tabah A, Timsit JF; EUROBACT-2 Study Group, the European Society of Intensive Care Medicine (ESICM), the European Society of Clinical Microbiology, the Infectious Diseases (ESCMID) Study Group for Infections in Critically Ill Patients (ESGCIP) and the OUTCOMEREA Network. Loiodice A, et al. Clin Microbiol Infect. 2024 Dec;30(12):1559-1568. doi: 10.1016/j.cmi.2024.09.011. Epub 2024 Sep 24. Clin Microbiol Infect. 2024. PMID: 39326671 Free article.
The polymyxin-B direct hemoperfusion OPTimal Initiation timing with Catecholamine PMX-OPTIC study: A multicenter retrospective observational study.
Nakamura K, Okazaki T, Tampo A, Mochizuki K, Kanda N, Ono T, Yanagita K, Shimomura T, Murase T, Saito K, Hirayama T, Ito T, Ogawa K, Nakamura M, Oda T, Morishima T, Fukushima T, Yasui H, Akashi N, Oshima K, Kawarazaki H, Akiba T, Uemura S, Honma Y, Nitta K, Okamoto K, Takaki S, Takeda H, Yamashita C. Nakamura K, et al. Among authors: takaki s. Artif Organs. 2025 Feb;49(2):218-228. doi: 10.1111/aor.14865. Epub 2024 Sep 18. Artif Organs. 2025. PMID: 39291793
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma.
Mori N, Tamaki N, Takaki S, Tsuji K, Tada T, Nakamura S, Ochi H, Mashiba T, Doisaki M, Marusawa H, Kobashi H, Fujii H, Ogawa C, Nonogi M, Arai H, Uchida Y, Urawa N, Narita R, Akahane T, Kondo M, Yasui Y, Tsuchiya K, Izumi N, Kurosaki M. Mori N, et al. Among authors: takaki s. Invest New Drugs. 2024 Oct;42(5):559-565. doi: 10.1007/s10637-024-01470-y. Epub 2024 Aug 30. Invest New Drugs. 2024. PMID: 39212893
Change in Liver Function in Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma.
Tamaki N, Mori N, Takaki S, Tsuji K, Tada T, Nakamura S, Ochi H, Mashiba T, Doisaki M, Marusawa H, Kobashi H, Fujii H, Ogawa C, Nonogi M, Arai H, Uchida Y, Urawa N, Narita R, Akahane T, Kondo M, Yasui Y, Tsuchiya K, Izumi N, Kurosaki M. Tamaki N, et al. Among authors: takaki s. Anticancer Res. 2024 Sep;44(9):3913-3918. doi: 10.21873/anticanres.17219. Anticancer Res. 2024. PMID: 39197893
Correction: Presentation, management, and outcomes of older compared to younger adults with hospital-acquired bloodstream infections in the intensive care unit: a multicenter cohort study.
Margalit I, Yahav D, Hoffman T, Tabah A, Ruckly S, Barbier F, Singer P, Timsit JF, Prendki V, Buetti N; EUROBACT-2 Study Group, the European Society of Intensive Care Medicine (ESICM), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Groups for Infections in Critically Ill Patients (ESGCIP) and Infections in the Elderly (ESGIE), and the OUTCOMEREA Network. Margalit I, et al. Infection. 2024 Dec;52(6):2565-2566. doi: 10.1007/s15010-024-02377-9. Infection. 2024. PMID: 39186219 Free PMC article. No abstract available.
333 results